James Nagarajah
Overview
Explore the profile of James Nagarajah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prive B, Govers T, Israel B, Janssen M, Timmermans B, Peters S, et al.
Eur J Nucl Med Mol Imaging
. 2025 Mar;
PMID: 40072531
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is currently under evaluation for detecting clinically significant prostate cancer. The PSMA-PET/CT may complement the current standard diagnostic pathway for...
2.
Patrianesha B, Peters S, Hardiansyah D, Ritawidya R, Prive B, Nagarajah J, et al.
Phys Med
. 2024 Dec;
129():104868.
PMID: 39642576
Purpose: This study aimed to determine the effect of model selection on simplified dosimetry for the kidneys using Bayesian fitting (BF) and single-time-point (STP) imaging. Methods: Kidney biokinetics data of...
3.
Loeff C, van Gemert W, Prive B, van Oort I, Hermsen R, Somford D, et al.
EJNMMI Rep
. 2024 Nov;
8(1):38.
PMID: 39592501
Aim: The objective of this study was to compare the detection rates of [F]PSMA-1007 and [F]Fluciclovine in early biochemical recurrence (BCR) of prostate cancer, i.e. with low prostate-specific antigen (PSA)...
4.
Prive B, Muselaers C, van Oort I, Janssen M, Peters S, van Gemert W, et al.
Front Nucl Med
. 2024 Oct;
2:863101.
PMID: 39354959
Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen...
5.
van Ruitenbeek N, Uijen M, Driessen C, Peters S, Prive B, van Engen-van Grunsven A, et al.
Theranostics
. 2024 Sep;
14(14):5388-5399.
PMID: 39310108
There is an urgent need for novel systemic therapies for recurrent/systemic salivary gland cancer, as current treatment options are scarce. [Ga]Ga-PSMA-11 PET/CT revealed relevant uptake of prostate-specific membrane antigen (PSMA)...
6.
Morris M, Castellano D, Herrmann K, de Bono J, Shore N, Chi K, et al.
Lancet
. 2024 Sep;
404(10459):1227-1239.
PMID: 39293462
Background: [Lu]Lu-PSMA-617 (Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed...
7.
Slootbeek P, Luna-Velez M, Prive B, van der Doelen M, Kloots I, Pamidimarri Naga S, et al.
Theranostics
. 2024 Sep;
14(12):4555-4569.
PMID: 39239510
PSMA-targeting radioligand therapy (PSMA-RLT) has shown promise in metastatic castration-resistant prostate cancer (mCRPC), particularly in PSMA-avid tumours. However, predicting response remains challenging. Preclinical data suggests aberrant p53-signalling as a predictor...
8.
van Houten P, Nagarajah J, Walraven J, Jaeger M, van Engen-van Grunsven A, Smit J, et al.
Eur Thyroid J
. 2024 Jul;
13(4).
PMID: 39047141
Objective: Patients with non-medullary thyroid carcinoma (NMTC) that are refractory to radioactive iodine (RAI) have a poor prognosis. Strategies for restoring the ability to take up iodine, so-called redifferentiation, are...
9.
Morris M, de Bono J, Nagarajah J, Sartor O, Wei X, Nordquist L, et al.
Cancer
. 2024 Jul;
130(20):3426-3435.
PMID: 39031642
Background: [Lu]Lu-PSMA-617 (Lu-PSMA-617) plus protocol-permitted standard of care (SOC) prolonged overall survival (OS) and radiographic progression-free survival (rPFS) versus SOC in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate...
10.
Prive B, Israel B, Janssen M, van der Leest M, de Rooij M, van Ipenburg J, et al.
Radiology
. 2024 May;
311(2):e231879.
PMID: 38771185
Background Multiparametric MRI (mpMRI) is effective for detecting prostate cancer (PCa); however, there is a high rate of equivocal Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions and false-positive...